MAP2K7 and melanoma: As such, MEK inhibitors are approved for second line treatment of B-RAF inhibitor resistance in melanoma and the combination of B-RAF and MEK inhibition is currently the standard upfront targeted-therapy for B-RAF-mutated melanoma.